Dr. John Lambert

Independent Consultant in Biotechnology, boasts over three decades of expertise in antibody and antibody-drug conjugates for anti-cancer therapeutics. With a rich history at ImmunoGen, Inc., includingroles as EVP, CSO, and Executive Vice President Emeritus & Distinguished Research Fellow, he's a recognized leader in cancer drug development, contributing to groundbreaking treatments like Kadcyla and Elahere.

Renowned Medical Oncologist with a decade-long tenure as Director of Clinical Research, he's a leading figure in pioneering cancer drug trials globally, specializing in antibody drug conjugates (ADCs) and contributing over 130 publications in Medical and Clinical Oncology.

Leader of Lyon's Anticancer Antibody team, spearheading groundbreaking research in hematology and solid tumors for over two decades. As a Professor at Hospices Civils de Lyon, he not only educates but also coordinates cancer research programs, showcasing pivotal leadership in medical advancements and academia.

Professor at Vrije Universiteit Brussel and Science Advisor at Precirix, leads groundbreaking research in oncology and molecular imaging. With a profound expertise in nanobody technology, Nick’s pioneering work involves developing targeted radiopharmaceuticals, notably the lead product CAM-H2, revolutionizing cancer therapy and diagnostics